Abstract
The pyrimidine bases uracil and thymine are degraded via the consecutive action of three enzymes to β-alanine and β-aminoisobutyric acid, respectively. To date, a number of patients have been described with a deficiency of dihydropyrimidine dehydrogenase and dihydropyrimidinase, the first two enzymes of the pyrimidine degradation pathway. In this study, we demonstrate that the first patient presenting with N-carbamyl-β-amino aciduria, due to a deficiency of β-ureidopropionase, was easily diagnosed at the metabolite level using HPLC–tandem mass spectrometry. Urinary analysis showed strongly elevated levels of N-carbamyl-β-alanine and N-carbamyl-β-aminoisobutyric acid, with normal or moderately increased levels of the pyrimidine bases and the dihydropyrimidines, respectively. The deficiency of β-ureidopropionase was confirmed by measuring all three enzymes of the pyrimidine degradation pathway. No activity of β-ureidopropionase could be detected in a liver biopsy of the patient, while a normal activity of dihydropyrimidine dehydrogenase and dihydropyrimidinase was present. Thus, HPLC–tandem mass specrometry proved to be a powerful tool for the initial diagnosis of patients with deficiency of β-ureidopropionase.
Similar content being viewed by others
REFERENCES
Assmann B, Göhlich-Ratmann G, Bräutigam C, et al (1998) Presumptive unreidopropionase deficiency as a new defect in pyrimidine catabolism found with in vitro H-NMR spectroscopy. J Inherit Metab Dis 21(supplement 2): 1.
Henry RJ (1964) Non-protein nitrogenous constituents. Clinical Chemistry, Principles and Techniques. New York: Hoeber Medical Division, Harper & Row, 292-299.
Naguib FNM, Kouni MH el, Cha S (1985) Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 45: 5405-5412.
Van Gennip AH, Busch S, Elzinga L, et al (1993) Application of simple chromatographic methods for the diagnosis of defects in pyrimidine degradation. Clin Chem 39: 380-385.
Van Gennip AH, Abeling NGGM, Vreken P, Van Kuilenburg ABP (1997a) Inborn errors of pyrimidine degradation: clinical, biochemical and molecular aspects. J Inherit Metab Dis 20: 203-213.
Van Gennip AH, De Abreu RA, Van Lenthe, et al (1997b) Dihydropyrimidinase deficiency: confirmation of the enzyme defect in dihydropyrimidinuria. J Inherit Metab Dis 20: 339-342.
Van Kuilenburg ABP, Vreken P, Abeling NGGM, et al (1999a) Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet 104: 1-9.
Van Kuilenburg ABP, Van Lenthe H, Van Gennip AH (1999b) Radiochemical assay for determination of dihydropyrimidinase activity using reversed-phase high-performance liquid chromatography. J Chromatogr B 729: 307-314.
Van Kuilenberg ABP, Van Lenthe H, Van Gennip AH (1999c) A radiochemical assay for β-ureidopropionase using radiolabeled N-carbamyl-β-alanine obtained via hydrolysis of [2-14C]5,6-dihydrouracil. Anal Biochem 272: 250-253.
Van Kuilenburg ABP, van Lenthe H, Tromp A, Veltman PCJ, Van Gennip AH (2000) Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency. Clin Chem 46: 9-17.
Van Lenthe H, van Kuilenburg ABP, Ito T, et al (2000) Defects in pyrimidine degradation identified by HPLC-electrospray tandem mass spectrometry of urine specimens or urine-soaked filter paper strips. Clin Chem 46: 1916-1922.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Van Kuilenburg, A.B.P., Van Lenthe, H., Assmann, B. et al. Detection of β-ureidopropionase deficiency with HPLC–electrospray tandem mass spectrometry and confirmation of the defect at the enzyme level. J Inherit Metab Dis 24, 725–732 (2001). https://doi.org/10.1023/A:1012997406132
Issue Date:
DOI: https://doi.org/10.1023/A:1012997406132